Compare Aurobindo Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GLENMARK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GLENMARK PHARMA AUROBINDO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 16.5 15.3 107.8% View Chart
P/BV x 3.4 2.1 159.5% View Chart
Dividend Yield % 0.3 0.5 65.6%  

Financials

 AUROBINDO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
AUROBINDO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs830712 116.6%   
Low Rs527484 109.0%   
Sales per share (Unadj.) Rs333.9349.6 95.5%  
Earnings per share (Unadj.) Rs40.432.8 123.1%  
Cash flow per share (Unadj.) Rs51.844.3 116.7%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.3 110.1%  
Book value per share (Unadj.) Rs237.1198.6 119.3%  
Shares outstanding (eoy) m585.91282.17 207.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.7 118.9%   
Avg P/E ratio x16.818.2 92.2%  
P/CF ratio (eoy) x13.113.5 97.3%  
Price / Book Value ratio x2.93.0 95.1%  
Dividend payout %6.26.1 101.5%   
Avg Mkt Cap Rs m397,569168,625 235.8%   
No. of employees `00017.912.0 148.3%   
Total wages/salary Rs m25,84920,561 125.7%   
Avg. sales/employee Rs Th10,956.98,196.0 133.7%   
Avg. wages/employee Rs Th1,447.71,708.1 84.8%   
Avg. net profit/employee Rs Th1,324.3768.5 172.3%   
INCOME DATA
Net Sales Rs m195,63698,655 198.3%  
Other income Rs m1,5532,081 74.6%   
Total revenues Rs m197,189100,736 195.7%   
Gross profit Rs m39,51915,858 249.2%  
Depreciation Rs m6,6803,259 204.9%   
Interest Rs m2,6263,346 78.5%   
Profit before tax Rs m31,76711,335 280.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8811,672 -52.7%   
Tax Rs m7,2693,756 193.5%   
Profit after tax Rs m23,6459,250 255.6%  
Gross profit margin %20.216.1 125.7%  
Effective tax rate %22.933.1 69.0%   
Net profit margin %12.19.4 128.9%  
BALANCE SHEET DATA
Current assets Rs m153,64566,968 229.4%   
Current liabilities Rs m120,42940,211 299.5%   
Net working cap to sales %17.027.1 62.6%  
Current ratio x1.31.7 76.6%  
Inventory Days Days13583 162.2%  
Debtors Days Days6481 78.4%  
Net fixed assets Rs m103,90933,322 311.8%   
Share capital Rs m586282 207.6%   
"Free" reserves Rs m138,32255,770 248.0%   
Net worth Rs m138,90856,052 247.8%   
Long term debt Rs m1,80035,738 5.0%   
Total assets Rs m264,544132,888 199.1%  
Interest coverage x13.14.4 298.5%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.7 99.6%   
Return on assets %9.99.5 104.8%  
Return on equity %17.016.5 103.1%  
Return on capital %23.817.8 133.8%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31662,998 154.5%   
Fx outflow Rs m40,58922,859 177.6%   
Net fx Rs m56,72740,140 141.3%   
CASH FLOW
From Operations Rs m16,22013,242 122.5%  
From Investments Rs m-28,768-6,990 411.6%  
From Financial Activity Rs m19,191-7,387 -259.8%  
Net Cashflow Rs m6,656-2,971 -224.1%  

Share Holding

Indian Promoters % 54.1 48.3 112.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 6.9 115.2%  
FIIs % 27.7 34.4 80.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 56,727 122.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; HCL Technologies & Bajaj Finance Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note, tracking mixed global cues as coronavirus cases continue to surge across the world.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 8, 2020 12:53 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SUN PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS